Comparative ecotoxicological hazard assessment of beta-blockers and their human metabolites using a mode-of-action-based test battery and a QSAR approach

Environmental Science and Technology

Volumn 40, Issue 23, 2006, Pages 7402-7408

  Escher, Beate I ^a   Bramaz, Nadine ^a   Richter, Manuela ^a   Lienert, Judit ^a  

^a SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENVIRONMENTAL ENGINEERING; HEALTH HAZARDS; METABOLITES; TOXIC MATERIALS; TOXICITY; YEAST;

ATENOLOL; METOPROLOL;

ALCOHOLS;

ANDROGEN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCIDE; DRUG METABOLITE; ESTROGEN; METOPROLOL; PROPRANOLOL;

ALCOHOLS; ENVIRONMENTAL ENGINEERING; HEALTH HAZARDS; METABOLITES; TOXIC MATERIALS; TOXICITY; YEAST;

BIOASSAY; DRUG; ECOTOXICOLOGY; HAZARD ASSESSMENT; HYDROPHOBICITY; ORGANIC COMPOUND; ORGANIC POLLUTANT; PHYTOTOXICITY; RISK ASSESSMENT;

ARTICLE; BIOTRANSFORMATION; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); ECOTOXICITY; ENERGY TRANSFER; GREEN ALGA; HYDROPHOBICITY; METABOLISM; NONHUMAN; PHOTOSYNTHESIS; PHYTOTOXICITY; POLLUTANT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RISK ASSESSMENT; SCREENING TEST;

ADRENERGIC BETA-ANTAGONISTS; ALGAE, GREEN; ATENOLOL; ENDPOINT DETERMINATION; HUMANS; LIPOSOMES; METOPROLOL; PHOTOSYNTHESIS; PROPRANOLOL; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RISK ASSESSMENT; TOXICITY TESTS; WATER POLLUTANTS, CHEMICAL;

ALGAE; CHLOROPHYTA;

EID: 33845331772     PISSN: 0013936X     EISSN: None     Source Type: Journal    
DOI: 10.1021/es052572v     Document Type: Article

References (48)

1. Halling-Sørensen, B.; Nors Nielsen, S.; Lanzky, P. F.; Ingerslev, F.; Holten Lützhøft, H.; Jørgensen, S. E. Occurrence, fate, and effect of pharmaceutical substances in the environment - a review. Chemosphere 1998, 36, 357-393.
2. Daughton, C.; Ternes, T. Pharmaceuticals and personal care products in the environment: agents of subtle change? Environ. Health Perspect. 1999, 107, Supp. 6, 907-937.
3. Ternes, T. A. Occurrence of drugs in German sewage treatment plants and rivers. Chemosphere 1998, 32, 3245-3260.
4. Kolpin, D. W.; Furlong, E. T.; Meyer, M. T.; Thurman, E. M.; Zaugg, S. D. Pharmaceuticals, hormones and other organic contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ. Sci. Technol. 2002, 36, 1201-1211.
5. Calamari, D.; Zuccato, E.; Castiglioni, S.; Bagnati, R.; Fanelli, R. Strategic survey of therapeutic drugs in the rivers Po and Lambro in northern Italy. Environ. Sci. Technol. 2003, 37, 1241-1248.
6. Paxeus, N. Removal of selected nonsteroidal antiinflammatory drugs (NSAIDs), gemfibrozil, carbamazepine, beta-blockers, trimethoprim and triclosan in conventional wastewater treatment plants in five EU countries and their discharge to the aquatic environment. Water Sci. Technol. 2004, 50, 253-260.
7. Daughton, C. G. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. I. Rationale for and avenues toward a green pharmacy. Environ. Health Perspect. 2003, 111, 757-774.
8. Daughton, C. G. Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health. II. Drug disposal, waste reduction, and future directions. Environ. Health Perspect. 2003, 111, 775-785.
9. EMEA Draft Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use CHMP/SWP/4447/00; The European Agency for the Evaluation of Medicinal Products, accessible at http://www.emea.eu.int/pdfs/human/swp/ 444700en.pdf, 2005.
10. European Commission Technical Guidance Document in Support of Commission Directive 93/67/EEC on Risk Assessment for New Notified Substances, Commission Regulation (EC) No 1488/94 on Risk Assessment for Existing Substances, and Directive 98/8/EC of the European Parliament and of the Council Concerning the Placing of Biocidal Products on the Market; Office for Official Publications of the European Communities, accessible at http://ecb.jrc.it/, 2003.
11. Stuer-Laudridson, F.; Birkved, M.; Hansen, L.; Holten Lützhoft, H.; Halling-Sorensen, B. Environmental risk assessment of human pharmaceuticals in Denmark after normal therapeutic use. Chemosphere 2000, 40, 783-793.
12. Ferrari, B.; Mons, R.; Vollat, B.; Fraysse, B.; Paxeus, N.; Lo Giudice, R.; Pollio, A.; Garric, J. Environmental risk assessment of six human pharmaceuticals: Are the current environmental risk assessment procedures sufficient for the protection of the aquatic environment? Environ. Toxicol. Chem./SETAC2004, 23, 1344-1354.
13. Huschek, G.; Hansen, P. D.; Maurer, H. H.; Krengel, D.; Kayser, A. Environmental risk assessment of medicinal products for human use according to the European Commission recommendations. Environ. Toxicol. 2004, 226-240.
14. Borchard, U. Pharmacological properties of beta-adrenoreceptor blocking drugs. J. Clinical Basic Cardiology 1998, 1, 5-9.
15. Huggett, D. B.; Brooks, B. W.; Peterson, B.; Foran, C. M.; Schlenk, D. Toxicity of select beta adrenergic receptor-blocking pharmaceuticals (β-blockers) on aquatic organisms. Archives Environ. Contamin. Toxicol. 2002, 43, 229-235.
16. Villegas-Navarro, A.; Rosas-L, E.; Reyes, J. L. The heart of Daphnia magna: effects of four cardioactive drugs. Comp. Biochem. Physiol. C-Toxicol., & Pharmacol. 2003, 136, 127-134.
17. Länge, R.; Dietrich, D. Environmental risk assessment of pharmaceutical drug substances - conceptual considerations. Toxicol. Lett. 2002, 131, 97-104.
18. Seiler, J. P., Pharmacodynamic activity of drugs and ecotoxicology - can the two be connected? Toxicol. Lett. 2002, 131, 105-115.
19. Daughton, C. G. PPCP's in the Environment: future research-beginning with the end always in mind. In Pharmaceuticals in the Environment; Kümmerer, K., Ed.; Springer: New York, 2004; pp 463-495.
20. Knacker, T.; Duis, K.; Ternes, T.; Fenner, K.; Escher, B.; Schmitt, H.; Römbke, J.; Garric, J.; Hutchinson, T.; Boxall, A. B. A. The EU-project ERAPharm - Incentives for the further development of guidance documents? Environ. Sci. Pollut. Res. 2005, 12, 62-65.
21. Escher, B. I.; Hermens, J. L. M., Modes of action in ecotoxicology: their role in body burdens, species sensitivity, QSARs, and mixture effects. Environ. Sci. Technol. 2002, 36, 4201-4217.
22. Escher, B. I.; Bramaz, N.; Eggen, R. I. L.; Richter, M., In-vitro assessment of modes of toxic action of pharmaceuticals in aquatic life. Environ. Sci. Technol. 2005, 39, 3090-3100.
23. Saller, R. Praktische Pharmakologie. Eigenschaften gebräuchlicher Medikamente; Schattauer: Stuttgart, Germany, 1983.
24. Therapeutic Drugs; Churchill Livingstone: New York, 1991.
25. Disposition of Toxic Drugs and Chemicals in Man, fourth edition; Baselt, R. C., Cravey, R. H., Dollery, C., Boobis, A. R., Burley, D., Davies, D. M., Davies, D. S., Harrison, P. I., Orme, M. L. E., Park, B. K., Goldberg, L. I., Eds; Chemical Toxicology Institute: Foster City, CA, 2000.
26. Escher, B. I.; Schwarzenbach, R. P.; Westall, J. W. C. Evaluation of liposome-water partitioning of organic acids and bases: I. Development of sorption model. Environ. Sci. Technol. 2000, 34, 3954-3961.
27. International Standard Organisation Water quality-determination of the inhibitory effect of water samples on the light emission of Vibrio fischeri (luminescent bacteria test); EN ISO 11348-3, 1998.
28. Escher, B. I.; Bramaz, N.; Maurer, M.; Richter, M.; Sutter, D.; von Känel, C.; Zschokke, M. Screening test battery for pharmaceuticals in urine and wastewater. Environ. Toxicol. Chem. 2005, 24, 750-758.
29. Routledge, E.; Sumpter, J., Estrogenic activity of surfactants and some of their degradation products assessed during a recombinant yeast estrogen screen. Environ. Toxicol. Chem. 1996, 15, 241-248.
30. Sohoni, P.; Sumpter, J. P., Several environmental estrogenic compounds are also anti-androgens. J. Endocrinol. 1998, 158, 327-339.
31. International Standard Organisation Water quality - Determination of the genotoxicity of water and waste water using the umu-test; EN ISO 38415-3, 1996.
32. Verhaar, H. J. M.; van Leeuwen, C. J.; Hermens, J. L. M. Classifying environmental pollutants. 1: Structure-activity relationships for prediction of aquatic toxicity. Chemosphere 1992, 25, 471-491.
33. Johnsson, G.; Regardh, C. G. Clinical pharmacokinetics of β-adrenoreceptor blocking drugs. Clin. Pharmacokin. 1976, 1, 233-263.
34. Escher, B.; Schwarzenbach, R. P. Mechanistic studies on baseline toxicity and uncoupling as a basis for modeling internal lethal concentrations in aquatic organisms. Aquat. Sci. 2002, 64, 20-35.
35. Hansch, C.; Leo, A. Exploring QSAR. Fundamentals and Applications in Chemistry and Biology; American Chemical Society: Washington, DC, 1995.
36. Vaes, W. H. J.; Urrestarazu-Ramos, E.; Hamwick, C.; van Holstein. I.; Blaauboer, B. J.; Seinen, W.; Verhaar, H. J. M.; Hermens, J. L. M. Solid-phase microextraction as a tool to determine membrane/water partition coefficients and bioavailable concentrations in in-vitro systems. Chem. Res. Toxicol. 1997, 10, 1067-1072.
37. Escher, B. I.; Sigg, L. Chemical Speciation of Organics and of Metals at Biological Interfaces. In Physicochemical Kinetics and Transport at Biointerfaces; Van Leeuwen, H. P., Köster, W., Eds.; John Wiley & Sons: Chichester, 2004; Vol. 9, pp 205-271.
38. Schwarzenbach, R. P.; Gschwend, P. M.; Imboden, D. M. Environmental Organic Chemistry, second edition; Wiley: New York, 2003.
39. Boxall, A. B. A.; Sinclair, C. J.; Fenner, K.; Kolpin, D.; Maud, S. J. When synthetic chemicals degrade in the environment. Environ. Sci. Technol. 2004, 38, 369A-375A.
40. Krämer, S. Liposome/water partitioning: theory, techniques, and applications. In Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies; Testa, B., Waterbeemd, V., Folkers, G., Guy, R., Eds.; Verlag Helvetica Chimica Acta: Zürich, Switzerland, 2001; pp 401-428.
41. Escher, B. I.; Eggen, R.; Vye, E.; Schreiber, U.; Wisner, B.; Schwarzenbach, R. P. Baseline toxicity (narcosis) of organic chemicals determined by membrane potential measurements in energy-transducing membranes. Environ. Sci. Technol. 2002, 36, 1971-1979.
42. Zhao, Y. T.; Cronin, M. T.; Dearden, J. C. Quantitative Structure-Activity Relationships of chemicals acting by nonpolar narcosis - theoretical considerations. Quant. Struct.-Act. Relat. 1998, 17, 131-138.
43. Oda, J.; Nakamura, S. I.; Oki, I.; Kato, T.; Shinagawa, H. Evaluation of the new system (umu-test) for the detection of environmental mutagens and carcinogens. Mutat. Res. 1985, 147, 219-229.
44. Cleuvers, M. Initial risk assessment for three beta-blockers found in the aquatic environment. Chemosphere 2005, 59, 199-205.
45. Pauletti, G. M.; Wunderli-Allenspach, H. Partitioning coefficients in vitro: artificial membranes as standardized distribution model. Eur. J. Pharm. Sci. 1994, 1, 273-282.
46. Betageri, G. V.; Rogers, J. A. Thermodynamics of partitioning of beta-blockers in the n-octanol-buffer and liposome systems. Int. J. Pharm. 1987, 36, 165-173.
47. Balon, K.; Riebesehl, B. U.; Muller, B. W. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm. Res. 1999, 16, 882-888.
48. Villeneuve, D.; Blankenship, A.; Giesy, J. Derivation and application of relative potency estimates based on in-vitro bioassays. Environ. Toxicol. Chem./SETAC 2000, 19, 2835-2843.